| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;99:2530-2536.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Antibodies to Platelet Factor 4–Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight Heparin
Clinical Implications for Heparin-Induced Thrombocytopenia
From the Departments of Hematology (C.P., S.I., Y.G.), Anesthesiology (M.A.M.), and Cardiac Surgery (M.M.), Hôpital Trousseau, Tours, and the Department of Immunology (J.A., A.M.V.), Serbio, Gennevilliers, France.
Correspondence to Dr Yves Gruel, MD, Department of Hematology, Hôpital Trousseau, 37044 Tours Cedex, France. E-mail gruel{at}med.univ-tours.fr
Background—Cardiopulmonary bypass (CPB) induces platelet activation with release of platelet factor 4 (PF4), and patients are exposed to high doses of heparin (H). We investigated whether this contributes to the development of antibodies to H-PF4 and heparin-induced thrombocytopenia (HIT).
Methods and Results—CPB was performed with unfractionated heparin
(UFH) in 328 patients. After surgery, patients received UFH (calcium
heparin, 200 IU · kg-1 · d-1)
(group 1, n=157) or low-molecular-weight heparin (LMWH, Dalteparin,
5000 IU once daily) (group 2, n=171). Eight days after surgery,
antibodies to H-PF4 were present in 83 patients (25.3%), 46 in
group 1 and 37 in group 2 (P=0.12). Most patients (61%)
had IgG1 to H-PF4, but only 8 samples with antibodies induced
platelet activation with positive results on serotonin
release assay. HIT occurred in 6 patients in group 1, but no
thrombocytopenia was observed in subjects receiving LMWH, although 2
had high levels of antibodies with positive serotonin
release assay results. When antibodies to H-PF4 were present, mean
platelet counts were lower only in patients with Fc
RIIA
R/R131 platelets.
Conclusions—These results provide evidence that the development of antibodies to H-PF4 after CPB performed with UFH is not influenced by the postoperative heparin treatment. The antibodies associated with high risk of HIT are mainly IgG1, which is present at high titers in the plasma of patients continuously treated with UFH.
Key Words: cardiopulmonary bypass • heparin • platelets • antibodies
This article has been cited by other articles:
 |
|
 |
|
  D. Paparella, G. Scrascia, A. Galeone, M. Coviello, G. Cappabianca, M. T. Venneri, B. Favoino, M. Quaranta, L. de Luca Tupputi Schinosa, and T. E. Warkentin Formation of anti-platelet factor 4/heparin antibodies after cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1456 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Shelat, A. Tomaski, and E. S. Pollak Serologic Results in >1000 Patients With Suspected Heparin-Induced Thrombocytopenia Clinical and Applied Thrombosis/Hemostasis, October 1, 2008; 14(4): 410 - 414. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 381S - 453S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fareed, R. L. Bick, G. Rao, S. Z. Goldhaber, A. Sasahara, H. L. Messmore, D. A. Happensteadt, and A. Nicolaides The Immunogenic Potential of Generic Version of Low-Molecular-Weight Heparins May Not be the Same as the Branded Products Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 5 - 7. [PDF]
|
|
|
|
 |
|
 S. Suvarna, B. Espinasse, R. Qi, R. Lubica, M. Poncz, D. B. Cines, M. R. Wiesner, and G. M. Arepally Determinants of PF4/heparin immunogenicity Blood, December 15, 2007; 110(13): 4253 - 4260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Merry Focus on Thrombin: Alternative Anticoagulants Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 256 - 260. [Abstract] [PDF]
|
|
|
|
 |
|
 E. A. Nutescu Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches Am. J. Health Syst. Pharm., June 1, 2007; 64(11_Supplement_7): S5 - S13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Kress, S. Aronson, M. L. McDonald, M. I. Malik, A. B. Divgi, A. J. Tector, F. X. Downey III, A. J. Anderson, M. Stone, and C. Clancy Positive Heparin-Platelet Factor 4 Antibody Complex and Cardiac Surgical Outcomes Ann. Thorac. Surg., May 1, 2007; 83(5): 1737 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Everett, R. Yeh, S. Y. Foo, D. Criss, E. M. Van Cott, M. Laposata, E. G. Avery, W. D. Hoffman, J. Walker, D. Torchiana, et al. Prevalence of Heparin/Platelet Factor 4 Antibodies Before and After Cardiac Surgery Ann. Thorac. Surg., February 1, 2007; 83(2): 592 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin, J.-A. I. Sheppard, C. S. Sigouin, T. Kohlmann, P. Eichler, and A. Greinacher Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia Blood, November 1, 2006; 108(9): 2937 - 2941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Close, M. Purohit, M. Tanos, and S. Hunter Should patients post-cardiac surgery be given low molecular weight heparin for deep vein thrombosis prophylaxis? Interactive CardioVascular and Thoracic Surgery, October 1, 2006; 5(5): 624 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wan, M. Warner, B. DeVarennes, P. Ergina, R. Cecere, and K. Lachapelle Clinical Presentation, Temporal Relationship, and Outcome in Thirty-Three Patients With Type 2 Heparin-Induced Thrombocytopenia After Cardiotomy Ann. Thorac. Surg., July 1, 2006; 82(1): 21 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rauova, L. Zhai, M. A. Kowalska, G. M. Arepally, D. B. Cines, and M. Poncz Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications Blood, March 15, 2006; 107(6): 2346 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bennett-Guerrero, T. F. Slaughter, W. D. White, I. J. Welsby, C. S. Greenberg, H. El-Moalem, and T. L. Ortel Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1567 - 1572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin, R. J. Cook, V. J. Marder, J.-A. I. Sheppard, J. C. Moore, B. I. Eriksson, A. Greinacher, and J. G. Kelton Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin Blood, December 1, 2005; 106(12): 3791 - 3796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Martel, J. Lee, and P. S. Wells Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis Blood, October 15, 2005; 106(8): 2710 - 2715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Gurbuz, W. G. Elliott, and A. A. Zia Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines Eur. J. Cardiothorac. Surg., January 1, 2005; 27(1): 138 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rauova, M. Poncz, S. E. McKenzie, M. P. Reilly, G. Arepally, J. W. Weisel, C. Nagaswami, D. B. Cines, and B. S. Sachais Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia Blood, January 1, 2005; 105(1): 131 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Gruel, C. Pouplard, D. Lasne, C. Magdelaine-Beuzelin, C. Charroing, and H. Watier The homozygous Fc{gamma}RIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes Blood, November 1, 2004; 104(9): 2791 - 2793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 311S - 337S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sobel The Incidence of Heparininduced Thrombocytopenia in Hospitalized Medical Patients Treated With Subcutaneous Unfractionated Heparin: A Prospective Cohort Study Perspectives in Vascular Surgery and Endovascular Therapy, June 1, 2004; 16(2): 147 - 149. [Abstract] [PDF]
|
|
|
|
|
|
A. F. Merry, P. J. Raudkivi, N. G. Middleton, J. M. McDougall, P. Nand, B. P. Mills, B. J. Webber, C. M. Frampton, and H. D. White Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery Ann. Thorac. Surg., March 1, 2004; 77(3): 925 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Harbrecht, B. Bastians, A. Kredteck, P. Hanfland, T. Klockgether, and C. Pohl Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin Neurology, February 24, 2004; 62(4): 657 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cannon, J. Butterworth, R. D. Riley, and J. M. Hyland Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery Ann. Thorac. Surg., February 1, 2004; 77(2): 711 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Koster and T. Fischer Management of Patients with Heparin-Induced Thrombocytopenia During Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 411 - 416. [Abstract] [PDF]
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann. Thorac. Surg., December 1, 2003; 76(6): 2121 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Warkentin, R. S. Roberts, J. Hirsh, and J. G. Kelton An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients Arch Intern Med, November 10, 2003; 163(20): 2518 - 2524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann. Thorac. Surg., August 1, 2003; 76(2): 638 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pravinkumar and N. R. Webster HIT/HITT and alternative anticoagulation: current concepts Br. J. Anaesth., May 1, 2003; 90(5): 676 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin Pork or beef? Ann. Thorac. Surg., January 1, 2003; 75(1): 15 - 16. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Francis, G. J. Palmer III, R. Moroose, and A. Drexler Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery Ann. Thorac. Surg., January 1, 2003; 75(1): 17 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Aird and E. J. Mark Case 15-2002 - A 53-Year-Old Man with a Myocardial Infarct and Thromboses after Coronary-Artery Bypass Grafting N. Engl. J. Med., May 16, 2002; 346(20): 1562 - 1570. [Full Text] [PDF]
|
|
|
|
|
|
M. P. Reilly, S. M. Taylor, N. K. Hartman, G. M. Arepally, B. S. Sachais, D. B. Cines, M. Poncz, and S. E. McKenzie Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through Fc{gamma}RIIA Blood, October 15, 2001; 98(8): 2442 - 2447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Konkle, T. L. Bauer, G. Arepally, D. B. Cines, M. Poncz, S. McNulty, R. N. Edie, and J. D. Mannion Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery Ann. Thorac. Surg., June 1, 2001; 71(6): 1920 - 1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R Deitcher and T. L Carman Heparin-induced thrombocytopenia: natural history, diagnosis, and management Vascular Medicine, May 1, 2001; 6(2): 113 - 119. [Abstract] [PDF]
|
|
|
|
|
|
A. Koster, M. Loebe, R. Sodian, E. V. Potapov, R. Hansen, J. Muller, F. Mertzlufft, G. J. Crystal, H. Kuppe, and R. Hetzer Heparin antibodies and thromboembolism in heparin-coated and noncoated ventricular assist devices J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0331 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. McCrae, J. B. Bussel, P. M. Mannucci, G. Remuzzi, and D. B. Cines Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders Hematology, January 1, 2001; 2001(1): 282 - 305. [Abstract] [Full Text] [PDF]
|
|